KRYSTAL-1 is an open-label, nonrandomized, multiple-expansion cohort phase 1/2 trial evaluating the safety and efficacy of the combination of adagrasib and cetuximab in patients with advanced KRAS ...

In January, the TKI lazertinib was greenlit by the European Commission in combination with the monoclonal antibody amivantamab to treat locally advanced NSCLC. This was following the FDA’s go ahead ...

Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg/kg in ...

Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg/kg in ...

Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in combination with cetuximab in patients with KRASG12V mutations - SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE ...

Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

ALX Oncology plans to launch new trials testing evorpacept with trastuzumab in HER2-positive breast cancer and with cetuximab in colorectal cancer, according to a March 5 release. Those layoffs ...

In Cohort 1, participants must not have received any prior systemic therapy and will receive SC amivantamab and oral lazertinib; in Cohort 2, participants must have had disease progression after ...

Yonsei University Hospital Cancer Center, Seoul, Republic of Korea.